We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Stryker: Company Is in Compliance Following Warning Letter

Stryker: Company Is in Compliance Following Warning Letter

July 19, 2007

Following its response to an FDA warning letter regarding its manufacturing facility in Cork, Ireland, Stryker considers its operations in full compliance with agency regulations, saying it has already employed the necessary corrective actions, the company told D&DL.

The agency issued the letter March 15 to Stryker’s Ireland operations following inspections Oct. 31 to Nov. 3, 2006. The facility primarily manufactures Duracon and Scorpio knee replacement components, as well as hip replacement systems such as Trident Acetabular, according to the letter, which was posted recently to the FDA website.

Stryker was cited for not appropriately documenting the required elements of risk analysis and root cause investigations and verification or effectivity measures regarding a correction for a packaging procedure, the letter said. In addition, a root cause investigation was not initiated and corrective and preventive actions were not taken for a nonconformance of inner- and outer-blister test samples for lots of CoCr hip stems.

Upcoming Events

  • 09Aug

    Medical Device Premarket Review Pathways and FDA Mechanisms for Expedited Review

  • 10Aug

    Gene & Cell Therapy Regulation: Comparability and Other New Developments

  • 08Sep

    Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections

  • 15Sep

    Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis

  • 20Sep

    Building a World-Class Pharmaceutical Advertising and Promotion Review Program

  • 22Sep

    FDA’s New Quality Management System Regulation: What the Proposed Harmonization with ISO 13485 Means for Devicemakers

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • Bioventus’ neXus SonaStar Elite Gets 510(k) Clearance

  • Civica Launches Its First Lower-Cost Generic Drug

  • Pulse Biosciences’ CellFX Gets 510(k) Clearance for Expanded Energy Settings

  • Merck to Face MDL Regarding Gardasil HPV Vaccine Side Effects

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing